Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Change in Cash (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Change in Cash for 6 consecutive years, with -$12.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Cash fell 3.75% year-over-year to -$12.1 million, compared with a TTM value of -$30.4 million through Sep 2025, up 43.87%, and an annual FY2024 reading of -$29.7 million, up 43.23% over the prior year.
  • Change in Cash was -$12.1 million for Q3 2025 at Barinthus Biotherapeutics, up from -$12.8 million in the prior quarter.
  • Across five years, Change in Cash topped out at $112.7 million in Q1 2021 and bottomed at -$19.8 million in Q4 2021.
  • Average Change in Cash over 5 years is $1.7 million, with a median of -$11.8 million recorded in 2025.
  • The sharpest move saw Change in Cash skyrocketed 7672.02% in 2021, then plummeted 296.43% in 2024.
  • Year by year, Change in Cash stood at -$19.8 million in 2021, then surged by 71.14% to -$5.7 million in 2022, then tumbled by 218.57% to -$18.2 million in 2023, then soared by 134.57% to $6.3 million in 2024, then crashed by 292.28% to -$12.1 million in 2025.
  • Business Quant data shows Change in Cash for BRNS at -$12.1 million in Q3 2025, -$12.8 million in Q2 2025, and -$11.8 million in Q1 2025.